Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00653354 |
Recruitment Status :
Completed
First Posted : April 4, 2008
Last Update Posted : December 5, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain, Post-surgical | Drug: valdecoxib Drug: valdecoxib/placebo Drug: placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 360 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Assessment Of The Analgesic Efficacy Of The Dosing Regimen Of Valdecoxib Compared To Placebo Patients In Pain Following Bunionectomy |
Study Start Date : | December 2002 |
Actual Study Completion Date : | March 2003 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Arm 1 |
Drug: valdecoxib
valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose |
Active Comparator: Arm 2 |
Drug: valdecoxib/placebo
valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose |
Placebo Comparator: Arm 3 |
Drug: placebo
placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose |
- Summed Pain Intensity Difference (categorical) through 24 hours (SPID 24) [ Time Frame: Day 1 ]
- Total Pain Relief through 24 hours (TOTPAR 24) [ Time Frame: Day 1 ]
- Patient's Global Evaluation of Study Medication [ Time Frame: Day 1 ]
- time between doses of study medication [ Time Frame: Day 1 ]
- Time-specific Pain Intensity Difference (PID) (categorical) [ Time Frame: 0, 2, 4, 6, 8, 10, 12, 16, and 24 hours ]
- time-specific pain relief [ Time Frame: 2, 4, 6, 8, 10, 12, 16, and 24 hours ]
- time-specific PID (VAS) [ Time Frame: 0, 2, 4, 6, 8, 10, 12, 16, and 24 hours ]
- Summed Pain Intensity (SPID)24 (VAS) [ Time Frame: 0, 2, 4, 6, 8, 10, 12, 16, and 24 hours ]
- time to rescue medication [ Time Frame: 2, 4, 6, 8, 10, 12, 16, and 24 hours ]
- percent of patients who took rescue medication [ Time Frame: Day 1 ]
- Patient's Satisfaction Questionnaire [ Time Frame: Day 1 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who underwent an uncomplicated primary unilateral first metatarsal bunionectomy surgery (with or without ipsilateral hammer toe repair) requiring open manipulation of bone with periosteal elevation under regional anesthesia (Mayo block)
- Patients had a Baseline pain intensity of moderate or severe on a categorical scale and ≥45 mm on a VAS
Exclusion Criteria:
- Patients who were scheduled to undergo other surgical procedures that would be expected to produce a greater degree of surgical trauma than the orthopedic procedure alone
- Patients treated with patient controlled analgesia (PCA) subsequent to the end of anesthesia
- Patients treated with long-acting local anesthetics or local anesthetics coadministered with epinephrine injected into the index joint space
- Patients expected to require analgesics or other agents other than study medication during the 8 hours preceding administration of study medication through the end of the treatment period, that could confound assessment of the analgesic response, specifically excluded were tricyclic antidepressants, tranquilizers, neuroleptics, neuroleptic antiemetics, cyclooxygenase-2 inhibitors, nonsteroidal antiinflammatory drugs, and corticosteroids

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00653354
United States, Arizona | |
Pfizer Investigational Site | |
Phoenix, Arizona, United States, 85015 | |
Pfizer Investigational Site | |
Phoenix, Arizona, United States, 85016 | |
Pfizer Investigational Site | |
Phoenix, Arizona, United States, 85020 | |
Pfizer Investigational Site | |
Phoenix, Arizona, United States, 85032 | |
Pfizer Investigational Site | |
Tempe, Arizona, United States, 85281 | |
United States, California | |
Pfizer Investigational Site | |
Anaheim, California, United States, 92701 | |
Pfizer Investigational Site | |
Chula Vista, California, United States, 91911 | |
Pfizer Investigational Site | |
San Diego, California, United States, 92114 | |
Pfizer Investigational Site | |
Santa Ana, California, United States, 92701 | |
Pfizer Investigational Site | |
Tustin, California, United States, 92780 | |
United States, Kentucky | |
Pfizer Investigational Site | |
Lexington, Kentucky, United States, 40504 | |
Pfizer Investigational Site | |
Lexington, Kentucky, United States, 40509 | |
Pfizer Investigational Site | |
Lexington, Kentucky, United States, 40515 | |
United States, Pennsylvania | |
Pfizer Investigational Site | |
Altoona, Pennsylvania, United States, 16602 | |
Pfizer Investigational Site | |
Duncansville, Pennsylvania, United States, 16635 | |
United States, Tennessee | |
Pfizer Investigational Site | |
Johnson City, Tennessee, United States, 37601 | |
Pfizer Investigational Site | |
Johnson City, Tennessee, United States, 37604 | |
United States, Texas | |
Pfizer Investigational Site | |
San Antonio, Texas, United States, 78229 | |
Pfizer Investigational Site | |
San Antonio, Texas, United States, 78240 | |
United States, Utah | |
Pfizer Investigational Site | |
Salt Lake City, Utah, United States, 84117 | |
Pfizer Investigational Site | |
Salt Lake City, Utah, United States, 84123 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Director, Clinical Trial Disclosure Group, Pfizer, Inc. |
ClinicalTrials.gov Identifier: | NCT00653354 |
Other Study ID Numbers: |
VALA-0513-149 A3471086 |
First Posted: | April 4, 2008 Key Record Dates |
Last Update Posted: | December 5, 2018 |
Last Verified: | December 2018 |
hallux valgus |
Valdecoxib Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic |
Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents |